Altox

Database / Pharmaceutical impurity

Pharmaceutical impurity

1-Cyclopropyl-6-fluoro-7-(piperazin-1-yl)quinolin-4(1H)-one (Decarboxylated Compound)

1-Cyclopropyl-6-fluoro-7-(piperazin-1-yl)quinolin-4(1H)-one (Decarboxylated Compound) is listed in the pharmaceutical impurity collection under CAS 105394-83-0. Its represented structure has formula C16H18FN3O and a calculated molecular weight of 287.34 g/mol.

2D chemical structure

O N N H N F

Chemical identity

Catalog name
1-Cyclopropyl-6-fluoro-7-(piperazin-1-yl)quinolin-4(1H)-one (Decarboxylated Compound)
Common name
Not available
Chemical name
1-cyclopropyl-6-fluoro-7-piperazin-1-ylquinolin-4-one
CAS
105394-83-0
SMILES
O=c1ccn(C2CC2)c2cc(N3CCNCC3)c(F)cc12
InChI
InChI=1S/C16H18FN3O/c17-13-9-12-14(10-15(13)19-7-4-18-5-8-19)20(11-1-2-11)6-3-16(12)21/h3,6,9-11,18H,1-2,4-5,7-8H2
InChIKey
QDYUSAJJDOBXBM-UHFFFAOYSA-N
Associated API
Matrix - API Family Ciprofloxacin Hydrochloride

Record ID: Af07403c7a4f3

Computed properties

C16H18FN3O Molecular formula
287.338 g/molMolecular weight
287.1434 DaMonoisotopic exact mass
37.27 ŲTopological polar surface area
1.8851 Calculated LogP (Wildman–Crippen)
81.5197 cm³/molMolar refractivity (Wildman–Crippen)
3 countHydrogen-bond acceptors
1 countHydrogen-bond donors

Descriptors are calculated from the displayed SMILES. Calculated LogP is not a measured partition coefficient or a pH-specific LogD.

Molecular descriptor profile

Descriptor radar

Mol. weight LogP TPSA HBA HBD Rotatable 25 50 75 100

Structural feature counts

0 2 4 Count H-bond acceptors H-bond donors Rotatable bonds Rings Aromatic rings Stereo centers

Element composition

C F H N O 0 4 8 12 16 Number of atoms

Radar scale: 0–100 percentile within 25,771 distinct represented structures in this release, using the midpoint rank for ties. Larger values indicate a higher descriptor rank, not greater safety or toxicity. Element counts include hydrogen and combine isotopes under each element.

Radar values and percentile reference
DescriptorValuePercentile
Molecular weight287.33840.37
Calculated LogP (Wildman–Crippen)1.885140.43
Topological polar surface area37.2718.09
Hydrogen-bond acceptors333.13
Hydrogen-bond donors138.08
Rotatable bonds (strict)224.16

Complete molecular descriptors

PropertyCalculated valueUnit / type
Molecular formulaC16H18FN3Odimensionless
Molecular weight287.338g/mol
Monoisotopic exact mass287.1434Da
Topological polar surface area37.27Ų
Calculated LogP (Wildman–Crippen)1.8851dimensionless
Molar refractivity (Wildman–Crippen)81.5197cm³/mol
Hydrogen-bond acceptors3count
Hydrogen-bond donors1count
Rotatable bonds (strict)2count
Heavy atoms21count
Heteroatoms5count
Rings4count
Aromatic rings2count
Aliphatic rings2count
Saturated rings2count
Aromatic heterocycles1count
Aliphatic heterocycles1count
Saturated heterocycles1count
Aromatic carbocycles1count
Aliphatic carbocycles1count
Fraction of sp³ carbon atoms0.4375fraction
Formal charge0e
Disconnected components1count
Isotopically specified atoms0count
Potential atom stereocenters0count
Unspecified atom stereocenters0count
Spiro atoms0count
Bridgehead atoms0count
Labute approximate surface area121.7224Ų
Valence electrons110count
Radical electrons0count
Bertz complexity745.0059index
Balaban J1.8964index

Ring categories overlap and should not be summed. No toxicity result, PDE, HBEL or acceptable intake is inferred from these descriptors.

Toxicological services and resources for 1-Cyclopropyl-6-fluoro-7-(piperazin-1-yl)quinolin-4(1H)-one (Decarboxylated Compound)

Qualification and safety assessment of 1-Cyclopropyl-6-fluoro-7-(piperazin-1-yl)quinolin-4(1H)-one (Decarboxylated Compound)

Explore toxicological qualification of 1-Cyclopropyl-6-fluoro-7-(piperazin-1-yl)quinolin-4(1H)-one (Decarboxylated Compound) and ICH M7 mutagenic impurity assessment of 1-Cyclopropyl-6-fluoro-7-(piperazin-1-yl)quinolin-4(1H)-one (Decarboxylated Compound) for evaluation of this impurity in its pharmaceutical context.

Where data gaps need to be addressed, resources include read-across assessment for 1-Cyclopropyl-6-fluoro-7-(piperazin-1-yl)quinolin-4(1H)-one (Decarboxylated Compound) and acceptable intake and limit justification for 1-Cyclopropyl-6-fluoro-7-(piperazin-1-yl)quinolin-4(1H)-one (Decarboxylated Compound). The relevant approach depends on the available evidence, exposure and duration of use.

Related Altox services and technical resources

Other catalogue designations with the same represented structure

These are separate catalogue entries; shared structure does not establish interchangeable pharmacopoeial designations.

Identity sources and calculation method

Identifiers originate from the source catalogues and available public identity records. InChI and InChIKey on this page are generated from the displayed SMILES. RDKit validation checks the molecular representation; it does not independently verify every catalogue assignment.

Discuss an assessment for 1-Cyclopropyl-6-fluoro-7-(piperazin-1-yl)quinolin-4(1H)-one (Decarboxylated Compound)

Explore Altox services and software through the Altox Pharma-Hub.